March 22, 2016
March 22, 2016 —
The Hemophilia and Thrombosis Treatment Center at UC San Diego Health has joined a nationwide clinical trial testing a potential gene therapy that may one day provide a better and long-lasting treatment for people with hemophilia B.
June 6, 2016
June 6, 2016 —
…using precision medicine, which emphasizes the use of individual genetics to refine cancer treatment, showed improved response and longer periods of disease remission, even in phase I trials.
November 9, 2021
November 9, 2021 —
Researchers reveal a previously unrealized complexity in cancer development, one that raises concerns and caution about targeting an enzyme popular in oncological treatments.
March 31, 2016
March 31, 2016 —
A protein once thought to be of little consequence has been found to be a central player in processes ranging from male fertility to early embryonic development, according to a study published in the March 31 online issue of Cell by researchers at the University of California, San Diego School…
March 13, 2023
March 13, 2023 —
UC San Diego researchers have identified a strong association between the product of a gene expressed in most cancers and elevated levels of white blood cells that produce antibodies within tumors, suggesting a new therapeutic target.
December 4, 2018
December 4, 2018 —
In lab and mouse experiments, UC San Diego School of Medicine researchers developed a method to leverage B cells to manufacture and secrete tumor-suppressing microRNAs.
October 11, 2013
October 11, 2013 —
…of the National Institutes of Health, to elucidate the genetics of glaucoma in persons of African descent.
June 1, 2015
June 1, 2015 —
…San Diego Health System have identified a previously unknown gene mutation that underlies this disorder.
July 6, 2015
July 6, 2015 —
Using human tumor samples and mouse models, researchers at University of California, San Diego School of Medicine and Moores Cancer Center discovered that cancer stem cell properties are determined by epigenetic changes — chemical modifications cells use to control which genes are turned on or off.
January 17, 2013
January 17, 2013 —
Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive – and thus vulnerable – to a novel cancer stem cell-targeting drug currently under development.